secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2021-09-15T23:59:59+00:00
Accession:  0001564590-21-047970
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA lifts clinical hold on KalVista's Phase 2 KVD824 trial for HAE prophylaxis
------------------------------------------------------------------------------

- FDA removed clinical hold on Phase 2 KOMPLETE trial of KVD824 for oral prophylactic treatment of hereditary angioedema.
- Clinical hold lifted after FDA review of KalVista's responses on certain preclinical studies of KVD824.
- Protocol refinements made; company working to resume study activities as soon as possible.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000156459021047970/0001564590-21-047970-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000156459021047970/kalv-8k_20210914.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-047970

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer